244 related articles for article (PubMed ID: 36107024)
21. Down-regulation of microRNA-200c is associated with drug resistance in human breast cancer.
Chen J; Tian W; Cai H; He H; Deng Y
Med Oncol; 2012 Dec; 29(4):2527-34. PubMed ID: 22101791
[TBL] [Abstract][Full Text] [Related]
22. [Effects of miRNA-21 on paclitaxel-resistance in human breast cancer cells].
Zhao ZL; Cai Y; Wang YY; Xia CL; Li CX; Chen SL; Yang QL; Chen CJ
Zhejiang Da Xue Xue Bao Yi Xue Ban; 2015 Jul; 44(4):400-9. PubMed ID: 26555418
[TBL] [Abstract][Full Text] [Related]
23. Inhibition of P-glycoprotein functionality by vandetanib may reverse cancer cell resistance to doxorubicin.
Jovelet C; Bénard J; Forestier F; Farinotti R; Bidart JM; Gil S
Eur J Pharm Sci; 2012 Aug; 46(5):484-91. PubMed ID: 22484209
[TBL] [Abstract][Full Text] [Related]
24. Reversal of P-glycoprotein-mediated multidrug resistance by CD44 antibody-targeted nanocomplexes for short hairpin RNA-encoding plasmid DNA delivery.
Gu J; Fang X; Hao J; Sha X
Biomaterials; 2015 Mar; 45():99-114. PubMed ID: 25662500
[TBL] [Abstract][Full Text] [Related]
25. miR-302a/b/c/d cooperatively inhibit BCRP expression to increase drug sensitivity in breast cancer cells.
Wang Y; Zhao L; Xiao Q; Jiang L; He M; Bai X; Ma M; Jiao X; Wei M
Gynecol Oncol; 2016 Jun; 141(3):592-601. PubMed ID: 26644266
[TBL] [Abstract][Full Text] [Related]
26. TGF-β1 elevates P-gp and BCRP in hepatocellular carcinoma through HOTAIR/miR-145 axis.
Kong J; Qiu Y; Li Y; Zhang H; Wang W
Biopharm Drug Dispos; 2019 Feb; 40(2):70-80. PubMed ID: 30698830
[TBL] [Abstract][Full Text] [Related]
27. Increased expression of P-glycoprotein and doxorubicin chemoresistance of metastatic breast cancer is regulated by miR-298.
Bao L; Hazari S; Mehra S; Kaushal D; Moroz K; Dash S
Am J Pathol; 2012 Jun; 180(6):2490-503. PubMed ID: 22521303
[TBL] [Abstract][Full Text] [Related]
28. Sensitization of ABCB1 overexpressing cells to chemotherapeutic agents by FG020326 via binding to ABCB1 and inhibiting its function.
Dai CL; Liang YJ; Chen LM; Zhang X; Deng WJ; Su XD; Shi Z; Wu CP; Ashby CR; Akiyama S; Ambudkar SV; Chen ZS; Fu LW
Biochem Pharmacol; 2009 Aug; 78(4):355-64. PubMed ID: 19410561
[TBL] [Abstract][Full Text] [Related]
29. Adenovirus-mediated p53 gene therapy reverses resistance of breast cancer cells to adriamycin.
Qi X; Chang Z; Song J; Gao G; Shen Z
Anticancer Drugs; 2011 Jul; 22(6):556-62. PubMed ID: 21637162
[TBL] [Abstract][Full Text] [Related]
30. Metformin inhibits P-glycoprotein expression via the NF-κB pathway and CRE transcriptional activity through AMPK activation.
Kim HG; Hien TT; Han EH; Hwang YP; Choi JH; Kang KW; Kwon KI; Kim BH; Kim SK; Song GY; Jeong TC; Jeong HG
Br J Pharmacol; 2011 Mar; 162(5):1096-108. PubMed ID: 21054339
[TBL] [Abstract][Full Text] [Related]
31. Reversal of drug resistance by JS-K and nitric oxide in ABCB1- and ABCG2-expressing multi-drug resistant human tumor cells.
Sinha BK; Perera L; Cannon RE
Biomed Pharmacother; 2019 Dec; 120():109468. PubMed ID: 31605952
[TBL] [Abstract][Full Text] [Related]
32. Resveratrol enhances chemosensitivity of doxorubicin in multidrug-resistant human breast cancer cells via increased cellular influx of doxorubicin.
Kim TH; Shin YJ; Won AJ; Lee BM; Choi WS; Jung JH; Chung HY; Kim HS
Biochim Biophys Acta; 2014 Jan; 1840(1):615-25. PubMed ID: 24161697
[TBL] [Abstract][Full Text] [Related]
33. Dasatinib reverses the multidrug resistance of breast cancer MCF-7 cells to doxorubicin by downregulating P-gp expression via inhibiting the activation of ERK signaling pathway.
Chen T; Wang C; Liu Q; Meng Q; Sun H; Huo X; Sun P; Peng J; Liu Z; Yang X; Liu K
Cancer Biol Ther; 2015; 16(1):106-14. PubMed ID: 25482933
[TBL] [Abstract][Full Text] [Related]
34. The PI3K subunits, P110α and P110β are potential targets for overcoming P-gp and BCRP-mediated MDR in cancer.
Zhang L; Li Y; Wang Q; Chen Z; Li X; Wu Z; Hu C; Liao D; Zhang W; Chen ZS
Mol Cancer; 2020 Jan; 19(1):10. PubMed ID: 31952518
[TBL] [Abstract][Full Text] [Related]
35. ABC transporter (P-gp/ABCB1, MRP1/ABCC1, BCRP/ABCG2) expression in the developing human CNS.
Daood M; Tsai C; Ahdab-Barmada M; Watchko JF
Neuropediatrics; 2008 Aug; 39(4):211-8. PubMed ID: 19165709
[TBL] [Abstract][Full Text] [Related]
36. MicroRNA-29a contributes to drug-resistance of breast cancer cells to adriamycin through PTEN/AKT/GSK3β signaling pathway.
Shen H; Li L; Yang S; Wang D; Zhong S; Zhao J; Tang J
Gene; 2016 Nov; 593(1):84-90. PubMed ID: 27523474
[TBL] [Abstract][Full Text] [Related]
37. Estrogen-mediated post transcriptional down-regulation of P-glycoprotein in MDR1-transduced human breast cancer cells.
Mutoh K; Tsukahara S; Mitsuhashi J; Katayama K; Sugimoto Y
Cancer Sci; 2006 Nov; 97(11):1198-204. PubMed ID: 16925584
[TBL] [Abstract][Full Text] [Related]
38. Development and characterisation of novel human multidrug resistant mammary carcinoma lines in vitro and in vivo.
Stein U; Walther W; Lemm M; Naundorf H; Fichtner I
Int J Cancer; 1997 Sep; 72(5):885-91. PubMed ID: 9311609
[TBL] [Abstract][Full Text] [Related]
39. The reversal effects of 3-bromopyruvate on multidrug resistance in vitro and in vivo derived from human breast MCF-7/ADR cells.
Wu L; Xu J; Yuan W; Wu B; Wang H; Liu G; Wang X; Du J; Cai S
PLoS One; 2014; 9(11):e112132. PubMed ID: 25372840
[TBL] [Abstract][Full Text] [Related]
40. MiR-222 and miR-29a contribute to the drug-resistance of breast cancer cells.
Zhong S; Li W; Chen Z; Xu J; Zhao J
Gene; 2013 Nov; 531(1):8-14. PubMed ID: 23994196
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
